心脏病综合解决方案平台

Search documents
微创系集体上涨 微创医疗宣布重组心律管理业务 打造心脏病综合解决方案平台
Zhi Tong Cai Jing· 2025-09-30 01:59
Core Viewpoint - The stocks of the MicroPort group have collectively risen, driven by the announcement of a restructuring in the cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with a subsidiary, MicroPort HeartLink, planning to merge with CRM Cayman [1] - Post-merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on solutions for arrhythmia management, with a pre-transaction equity value of USD 680 million [1] - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] Group 3: Strategic Intent - The restructuring is seen as a strategy to mitigate the pressure of meeting the "qualified listing" requirements for the cardiac rhythm management business [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - An agreement was made that if CRM does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]
微创医疗(00853):微创心通拟合并CRM Cayman 打造心脏病综合解决方案平台
智通财经网· 2025-09-29 15:07
公告称,合并协议所述交易符合微创心通业务的策略性发展,有助于微创心通建立一个具有全球布局的 心脏病产品平台,提供多元化产品及产品管线,并实现互补性协同效应。此等协同效应将扩大及多元化 微创心通现有业务,尤其在提升微创心通于结构性心脏病及心脏节律疾病解决方案的产品及产品管线、 研发能力、制造能力、分销渠道及市场拓展方面发挥作用。 智通财经APP讯,微创医疗(00853)发布公告,于2025年9月29日,CRM Cayman、微创心通及 MicroPort CardioFlow CRM Limited(合并附属公司)订立了一份合并协议。合并附属公司为一间于开曼群岛注册成 立的获豁免有限公司,并为微创心通间接全资拥有的附属公司。 根据合并协议,微创心通将透过合并附属公司以合并方式收购CRM Cayman。于该合并生效时, CRM Cayman将成为微创心通的间接全资拥有的附属公司,而作为代价,微创心通将以每股1.35港元的发行 价向CRM Cayman的股东(包括公司间接全资拥有附属公司MicroPort International Corp. Limited)配发及发 行若干新股份。完成合并后,CRM Cayma ...